Personalizing kidney treatment: can biomarkers predict who benefits from finerenone?
NCT ID NCT07717697
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study follows 425 adults with type 2 diabetes and chronic kidney disease who are taking finerenone, a standard medication. Researchers collect blood and urine samples over four months to look for biomarkers that predict whether the drug helps reduce kidney damage. The goal is to build a model that helps doctors tailor finerenone therapy to each patient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- finerenone
- What this could lead to
- If successful, this could help doctors predict which patients with diabetic kidney disease will benefit most from finerenone, enabling more personalized treatment.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. The 4-month follow-up is short, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- Fig leaf tea may shield kidneys from diabetes damage — a trial puts it to the test
- Can a nasal spray of insulin shield the aging brain from Post-Surgery confusion?
- Smartphone app could improve blood sugar control in type 2 diabetes
- Diabetes drug class may change how the bladder behaves
- Could donating blood help control diabetes and fatty liver?